Repressing CD147 is a novel therapeutic strategy for malignant melanoma

Xing Hu; Juan Su; Youyou Zhou; Xiaoyun Xie; Cong Peng; Zhimin Yuan; Xiang Chen

doi:10.18632/oncotarget.15709

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Repressing CD147 is a novel therapeutic strategy for malignant melanoma

Xing Hu, Juan Su _, Youyou Zhou, Xiaoyun Xie, Cong Peng, Zhimin Yuan and Xiang Chen

PDF | HTML | How to cite

Oncotarget. 2017; 8:25806-25813. https://doi.org/10.18632/oncotarget.15709

Metrics: PDF 2406 views | HTML 4545 views | ?

Abstract

Xing Hu1,2, Juan Su1,2,Youyou Zhou2, Xiaoyun Xie1,2, Cong Peng1,2, Zhimin Yuan3 and Xiang Chen1,2

1 Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China

2 Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China

3 Department of Genetics and Complex Diseases, Harvard T.H Chan School of Public Health, Boston, MA, USA

Correspondence to:

Juan Su, email:

Xiang Chen, email:

Keywords: cyclophilin A, CD147, melanoma, cell proliferation, MMPs

Received: December 21, 2016 Accepted: January 22, 2017 Published: February 25, 2017

Abstract

CD147/basigin, a transmembrane protein, is a member of the immunoglobulin super family. Accumulating evidence has revealed the role of CD147 in the development and progression of various cancers, including malignant melanoma (MM). MM is a malignancy of pigment-producing cells that causes the greatest number of skin cancer-related deaths worldwide. CD147 is overexpressed in MM and plays an important role in cell viability, apoptosis, proliferation, invasion, and metastasis, probably by mediating vascular endothelial growth factor (VEGF) production, glycolysis, and multi-drug resistance (MDR). As a matrix metalloproteinase (MMP) inducer, CD147 could also promote surrounding fibroblasts to secrete abundant MMPs to further stimulate tumor cell invasion. Targeting CD147 has been shown to suppress MM in vitro and in vivo, highlighting the therapeutic potential of CD147 silencing in MM treatment. In this review article, we discuss CD147 and its biological roles, regulatory mechanisms, and potential application as a molecular target for MM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15709

Publication Alerts

Reviews:

Repressing CD147 is a novel therapeutic strategy for malignant melanoma

Abstract